Cargando…
Pharmacological Strategy for Congenital Myasthenic Syndrome with CHRNE Mutations: A Meta-Analysis of Case Reports
BACKGROUND: Congenital myasthenic syndromes (CMSs) are a heterogeneous group of neuromuscular disorders. Mutations of the nicotinic acetylcholine receptor epsilon subunit gene (CHRNE) are the most common causes of these disorders. CMSs are gaining increasing recognition by clinicians. However, pharm...
Autores principales: | Huang, Kun, Luo, Yue-Bei, Bi, Fang-Fang, Yang, Huan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573743/ https://www.ncbi.nlm.nih.gov/pubmed/32727330 http://dx.doi.org/10.2174/1570159X18666200729092332 |
Ejemplares similares
-
CHRNE compound heterozygous mutations in congenital myasthenic syndrome: A case report
por: Yang, Kunfang, et al.
Publicado: (2018) -
Congenital myasthenic syndrome: phenotypic
variability in patients harbouring p.T159P
mutation in CHRNE gene
por: Ardissone, Anna, et al.
Publicado: (2017) -
A Novel Homozygous Variant in the CHRNE Gene in 2 Siblings with Congenital Myasthenic Syndrome
por: Chan, Cassie, et al.
Publicado: (2023) -
A case report of congenital myasthenic syndrome caused by a mutation in theCHRNE genein the Iranian population
por: FARJAMI, Zahra, et al.
Publicado: (2020) -
Pharmacological Treatments for Congenital Myasthenic Syndromes Caused by COLQ Mutations
por: Shao, Shuai, et al.
Publicado: (2023)